Introduction: The objectives of this study were to (a) assess the factors associated with weight
Methods:
The study was a retrospective cohort study using UK Clinical Practice Research Datalink linked to Hospital Episode Statistics (CPRD/HES) data. The association between baseline phenotypic factors and weight gain was assessed using logistic regression. Hospitalization incidence rates per 1000 person-years for major diabetes-related complications according to body mass index (BMI) at baseline were estimated from the data (observed) and compared to those obtained from a validated diabetes model (predicted).
Results: 11,071 patients were included in the analysis; approximately 40% gained weight in the first year following escalation to M ? S.
Baseline age, HbA1c and gender were found to be predictors of weight gain [odds ratios 0.99
(1-year increment), 1.11 (1% increment) and 0.81 (female vs male), respectively, p\0.001]. 
INTRODUCTION
The global prevalence of diabetes as of 2013 is estimated at 382 million, accounting for 11% (548 billion US dollars) of the total global healthcare spend [1] . By 2035, diabetes prevalence is expected to rise by 55% to 592 million and cost the global economy 627 billion US dollars [1] . The majority of the cost associated with type 2 diabetes is related to the management of diabetes-related macrovascular and microvascular complications, such as cerebrovascular and cardiovascular (CV) disease and diabetic retinopathy, nephropathy and neuropathy [2] . There is an increasing amount of epidemiological evidence relating body mass index (BMI) to increased risk of CV disease and all-cause mortality (ACM) in patients with type 2 diabetes [3, 4] . Importantly, CV and mortality risk equations typically incorporate the effects of elevated BMI indirectly via the inter-relationship between modifiable CV risk factors (such as cholesterol and systolic blood pressure) and BMI; this approach may underestimate the true morbidity and mortality risk. Consequently, the resource utilization associated with obesity in patients with type 2 diabetes may also be underestimated. identifier, #NCT00145925) [6] . They found that baseline factors associated with weight gain were younger age, higher HbA1c, Caucasian ethnicity and number of glucose-lowering medications. These studies illustrate that the identification of phenotypic characteristics that are predictive of weight gain at the time of treatment initiation or escalation may help to develop strategies for avoidance of weight gain [5] , and any downstream adverse patient outcomes and excess resource utilization associated with weight gain, among type 2 diabetes patients. Moreover, the accurate prediction of the health and resource consequences associated with the management of type 2 diabetes is crucial to inform decision making in healthcare.
With this in mind, the objectives of this study were to (a) assess the factors associated with weight gain in a population of type 2 diabetes patients escalating to the most common dual oral therapy regimen and (b) evaluate whether healthcare resource utilization associated with being overweight or obese is underestimated in typical health economic evaluations in type 2 diabetes.
METHODS

Data
Consistent with current consensus guidelines on the management of hyperglycemia in patients with type 2 diabetes, metformin (M) augmented with a sulfonylurea (S) (M ? S) is the predominant second-line oral diabetes therapy in clinical practice [7] . The addition of S to M is known to be associated with increased weight gain [7] . Hence, as a population, this cohort provides a potentially interesting case study to assess the relationship between BMI and healthcare resource utilization. Index date was defined as the date of addition of S to M. The following inclusion criteria were applied to obtain the study cohort ( Fig. 1 
Variable definitions: 'Prior complications' (pre-index history of CAD, CHF, neuropathy, stroke, retinopathy, nephropathy),'Respiratory/cerebrovascular complications' (=asthma, chronic obstructive pulmonary disease, cerebrovascular disease), 'Vascular complications' (=CAD, cerebrovascular disease, peripheral vascular disease, microalbuminuria, chronic kidney disease, retinopathy). History refers to history in 12-months prior to index date BMI body mass index, CAD coronary artery disease, CHF congestive heart failure, HbA1c hemoglobin A1c, HDL-C high density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, SD standard deviation a Overall n: 10,907 patients had a BMI record at baseline measurement at baseline and 12 months to be included in this analysis, which estimated the probability of weight gain, adjusting for relevant differences in patient characteristics at baseline. Model selection was based on a backwards general-specific methodology, eliminating statistically insignificant covariates, covariate transformations and interaction terms at the 0.05 level of testing to estimate baseline factors predictive of weight gain.
Observed vs Predicted Hospital Admissions
The association between hospitalizations (number of admissions and LOS) and weight status was assessed using BMI as the weight measurement. This was required to assess the relationship between observed and predicted hospitalizations, as the CDM uses BMI as a risk factor in estimating the incidence of complications. Patients were classified by their BMI at baseline: normal (C18.5 and \25), overweight (C25 and \30), obese (C30 and \35), and severe obese (C35).
Observed admissions were compared to the number of events (admissions) predicted by the CDM over a 3-year period, based on the number of patients, baseline demographics and risk factor profile of the cohort. Analysis was stratified by BMI at baseline. The corresponding total and average LOS of admissions from the CPRD data were descriptively summarized.
The observed vs predicted analysis was based on incidence rates to account for variable patient follow-up. For hospitalizations, the risk set was treated as discontinuous risk intervals (i.e., patients were not at risk of a subsequent hospitalization until they had completed the first hospitalization): person-time was calculated by excluding the duration of hospitalizations from the risk set (i.e., Analyses were undertaken using R version 2.12.2 (The R Foundation). 
RESULTS
Patient (Baseline) Phenotypic Profiles
Factors Predictive of Weight Gain
In the Table 2) .
Observed vs Predicted Hospital Admissions
Over the 3-year follow-up period, across BMI categories, the most to least common events associated with hospitalizations in the observed dataset (CPRD/HES) were ischemic heart disease (33%), end-stage renal disease (21%), congestive heart failure (20%), myocardial infarction (14%), stroke (13%), amputation (\1%) and blindness (0%). The observed incidence rates of hospitalizations per 1000 person-years associated with myocardial infarction, stroke, ischemic heart disease, congestive heart failure, 
4).
Observed vs Predicted Mortality
DISCUSSION
Study Objectives and Results
The aim of this study was to identify baseline patient characteristics predictive of weight gain and to assess whether typical health economic evaluations capture the excess secondary care healthcare resource utilization associated with weight gain using linked primary and secondary care data from the UK in people with a diagnosis of type 2 diabetes escalating from M to M ? S combination therapy.
Regarding the first objective of this study, understanding the baseline factors predictive of weight gain is important as it may help to inform both clinical and economic decision making. Where there are identifiable patient characteristics predictive of weight gain, these could help guide treatment decisions and define management strategies, potentially improving patient health outcomes and directing healthcare resources to efficient uses. We found that there are identifiable phenotypic characteristics predictive of weight gain in the M ? S cohort. Around 40% of patients gained CI confidence interval, HbA1c hemoglobin A1c, Pr ([IzI) probability being greater than z and less than -z, where z is the value of the standard normal distribution 
Diabetes Modeling
It was not the objective of this study to cast doubt over the predictive validity of the CDM. The model has been subject to a number of validation exercises and routinely participates in the Mount Hood challenge meetings, a forum for diabetes modelers to compare and furthermore, the CDM has been shown to capture the incidence of long-term diabetes-related complications with a high degree of accuracy [13] . Our concern rests with whether the risk equations typically used in diabetes models are failing to adequately capture the multiple comorbidities that can occur. The CDM model, as with most published contemporary type 2 diabetes models, is based on the United Kingdom Prospective Diabetes Study (UKPDS) 68 risk equations [14] . BMI features in only one of several risk prediction equations: coronary heart failure. Modeling under-predicted the incidence of myocardial infarction, stroke, ischemic heart disease, congestive heart failure and end-stage renal disease compared to the observed data. The results of this analysis suggest that BMI may have a much larger role to play in determining the risk of diabetes complications, as this analysis suggests higher BMI levels were associated with more hospitalizations. While this study reports an apparent trend of reduced LOS for increasing BMI, overall the findings of this research suggest that secondary healthcare resource utilization is higher for increasing BMI, as reflected by more frequent admission. The recent publication of the updated UKPDS 82 risk equations [15] , where BMI is a risk factor for a larger number of diabetes-related complications, further emphasizes the importance of accurately modeling the relationship between complication incidence as a function of increasing BMI.
A consequence of these findings is that long-term projections obtained from diabetes models may not adequately reflect the benefit of improved risk factor profiles. In particular, the value of diabetes management strategies that minimize weight gain may be underestimated as a result. It is noteworthy that the UKPDS equations are most commonly criticized for potentially over-predicting complication rates [10, 16] ; this study suggests they may significantly under-predict total burden associated with diabetes-related complications.
Diabetes models are central to informing decisions around product reimbursement and hence the treatment alternatives available to clinicians and ultimately patients. 
Study Limitations
The findings of this study are set against the following limitations. First, not all relevant confounding factors are captured in the CPRD/ HES databases. Thus, predicting association between BMI and resource use, and baseline factors predictive of weight gain is limited by the coverage and completeness of the data, though the databases contain significant detail on the patient characteristics most relevant to this analysis. There may be under-reporting for certain variables within the dataset; for example, the prevalence of congestive heart failure and nephropathy appears low. However, given the age distribution of the cohort, congestive heart failure prevalence around 3% is not surprising since these patients are probably not that far into their disease course as they have been users of M (first line) and have only just needed augmentation. Nephropathy can take several years to manifest, which may account for the apparently low rate observed; although other studies suggest a significant proportion of type 2 diabetes with a relatively short disease duration would have had nephropathy [17] .
Second, by nature, observational studies of this kind will be subject to 'confounding by indication', such that any observed patterns within the data are a function of patient phenotype, and patient phenotype is the reason for prescription of a specific therapy.
Restricting analysis to only M ? S patients minimizes this potential confounder. The inferences that can be made from the current analysis of observed versus predicted hospital admissions are indirectly strengthened by the analysis of observed versus predicted ACM, where estimates from CPRD and the CDM generally predicted the same survival probabilities over a 9-year period. Observed versus predicted survival estimates may have been closer, possibly due to the nature of mortality as an endpoint in that it may be better recorded in CPRD compared to events, and/or the estimation of mortality via UKPDS equations is more accurate; however, the precise reason cannot be determined from this data.
Finally, the CDM was used to evaluate the expected occurrence of events based on risk factor profiles observed in routine clinical practice; these estimates were compared against observed event rates. Statistical adjustment of the data, accounting for the influence of patient characteristics at baseline and over time on the observed relationship between hospitalization rates and BMI, was not undertaken given that the primary aim of this study was to assess the relationship between observed vs predicted hospital admissions in the context of economic evaluation. Thus, reported incidence rates should be interpreted as unadjusted estimates from an epidemiological perspective. 
CONCLUSION
